Lucid Diagnostics (LUCD) vs Nyxoah SA (NYXH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lucid Diagnostics (LUCD) has outperformed Nyxoah SA (NYXH) over the past year, losing 46.7% versus a loss of 78.7%. Over five years, LUCD leads with a -93.0% price change compared with -94.7% for NYXH. Nyxoah SA is the larger company by market cap ($138.5 million vs $121.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LUCD | NYXH |
|---|---|---|
| Share price | $0.638 | $1.36 |
| Market cap | $121.83M | $138.50M |
| 1-day change | -1.86% | +0.74% |
| YTD return | -40.36% | -70.43% |
| 1-year return | -46.71% | -78.72% |
| 5-year return | -93.05% | -94.67% |
| EPS (TTM) | $-0.44 | $-2.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.63 | $6.88 |
| 52-week low | $0.50 | $1.26 |
| Distance from 52-week high | -60.83% | -80.22% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +526.96% | +208.82% |
| Average volume | 1.35M | 275.85K |
| Shares outstanding | 190.95M | 101.84M |
| Employees | 82 | 153 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LUCD has outperformed NYXH by 32.0 percentage points over the past year.
About Lucid Diagnostics
LUCD stock →Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
Health Care · Medical/Dental Instruments · 82 employees
About Nyxoah SA
NYXH stock →Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea.
Health Care · Medical/Dental Instruments · 153 employees
LUCD vs NYXH FAQ
Which is bigger, Lucid Diagnostics or Nyxoah SA?
Nyxoah SA (NYXH) is larger, with a market capitalization of $138.50M compared with $121.83M for Lucid Diagnostics (LUCD).
Which stock has performed better over the past year, LUCD or NYXH?
LUCD returned -46.71% over the past 12 months, compared with -78.72% for NYXH (price return, excluding dividends). Past performance does not predict future results.
Are Lucid Diagnostics and Nyxoah SA in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.